<DOC>
	<DOCNO>NCT00877747</DOCNO>
	<brief_summary>Early interim-PET two course chemotherapy powerful outcome predictor advanced-stage Hodgkin Lymphoma ( HL ) patient treat adriamycin ( doxorubicin ) , bleomycin , vinblastine dacarbazine ( ABVD ) . Two-year Progression Free Survival PET-2 positive patient 12 % , optimal treatment patient subset still unknown . From January 2006 GITIL ( Gruppo Italiano Terapie Innovative nei Linfomi ) suggest early intensification chemotherapy BEACOPP [ Bleomycin , Etoposide , Adriamycin ( doxorubicin ) , Cyclophosphamide , Oncovin ( vincristine ) , Procarbazine , Prednisone ] ( 4 escalate + 4 baseline cycle ) HL patient positive PET-2 2 ABVD course . The investigator retrospectively record analyze data order evaluate strategy could benefit subset patient .</brief_summary>
	<brief_title>Early Chemotherapy Intensification Interim-Positron Emission Tomography ( PET ) Positive Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Patients advance Hodgkin 's lymphoma accord World Health Organization classification Age 1680 Not previously treat Stage IIB IVB stage IIA adverse prognostic factor ( 3 nodal site , ESR &gt; 50 mm , bulky lesion ) Written informed consent Patients age 80 Concomitant previously treat neoplastic disorder le 5 year diagnosis Hodgkin 's lymphoma Psychiatric disorder Uncontrolled infectious disease Impaired cardiac ( EF &lt; 50 % ) renal ( creatinine clearance &lt; 60 ml/m ) function Pregnancy lactation Uncompensated diabetes mellitus fast glucose level 200 mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>PET</keyword>
</DOC>